Cargando…

Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial

INTRODUCTION: There is currently no accurate method of measuring glomerular filtration rate (GFR) during acute kidney injury (AKI). Knowledge of how much GFR varies in stable subjects is necessary before changes in GFR can be attributed to AKI. We have designed a method of continuous measurement of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dixon, John J, Lane, Katie, Dalton, R Neil, Turner, Charles, Grounds, R Michael, MacPhee, Iain AM, Philips, Barbara J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336474/
https://www.ncbi.nlm.nih.gov/pubmed/25885409
http://dx.doi.org/10.1186/s12967-015-0414-3
_version_ 1782358473674063872
author Dixon, John J
Lane, Katie
Dalton, R Neil
Turner, Charles
Grounds, R Michael
MacPhee, Iain AM
Philips, Barbara J
author_facet Dixon, John J
Lane, Katie
Dalton, R Neil
Turner, Charles
Grounds, R Michael
MacPhee, Iain AM
Philips, Barbara J
author_sort Dixon, John J
collection PubMed
description INTRODUCTION: There is currently no accurate method of measuring glomerular filtration rate (GFR) during acute kidney injury (AKI). Knowledge of how much GFR varies in stable subjects is necessary before changes in GFR can be attributed to AKI. We have designed a method of continuous measurement of GFR intended as a research tool to time effects of AKI. The aims of this crossover trial were to establish accuracy and precision of a continuous infusion of low dose Iohexol (CILDI) and variation in GFR in stable volunteers over a range of estimated GFR (23-138 mL/min/1.73 m(2)). METHODS: We randomised 17 volunteers to GFR measurement by plasma clearance (PC) and renal clearance (RC) of either a single bolus of Iohexol (SBI; routine method), or of a continuous infusion of low dose Iohexol (CILDI; experimental method) at 0.5 mL/h for 12 h. GFR was measured by the alternative method after a washout period (4–28 days). Iohexol concentration was measured by high performance liquid chromatography/electrospray tandem mass spectrometry and time to steady state concentration (Css) determined. RESULTS: Mean PC was 76.7 ± 28.5 mL/min/1.73 m(2) (SBI), and 78.9 ± 28.6 mL/min/1.73 m(2) (CILDI), p = 0.82. No crossover effects occurred (p = 0.85). Correlation (r) between the methods was 0.98 (p < 0.0001). Bias was 2.2 mL/min/1.73 m(2) (limits of agreement −8.2 to 12.6 mL/min/1.73 m(2)) for CILDI. PC overestimated RC by 7.1 ± 7.3 mL/min/1.73 m(2). Mean intra-individual variation in GFR (CILDI) was 10.3% (p < 0.003). Mean ± SD Css was 172 ± 185 min. CONCLUSION: We hypothesise that changes in GFR >10.3% depict evolving AKI. If this were applicable to AKI, this is less than the 50% change in serum creatinine currently required to define AKI. CILDI is now ready for testing in patients with AKI. TRIAL REGISTRATION: This trial was registered with the European Union Clinical Trials Register (https://www.clinicaltrialsregister.eu/), registration number: 2010-019933-89.
format Online
Article
Text
id pubmed-4336474
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43364742015-02-22 Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial Dixon, John J Lane, Katie Dalton, R Neil Turner, Charles Grounds, R Michael MacPhee, Iain AM Philips, Barbara J J Transl Med Research INTRODUCTION: There is currently no accurate method of measuring glomerular filtration rate (GFR) during acute kidney injury (AKI). Knowledge of how much GFR varies in stable subjects is necessary before changes in GFR can be attributed to AKI. We have designed a method of continuous measurement of GFR intended as a research tool to time effects of AKI. The aims of this crossover trial were to establish accuracy and precision of a continuous infusion of low dose Iohexol (CILDI) and variation in GFR in stable volunteers over a range of estimated GFR (23-138 mL/min/1.73 m(2)). METHODS: We randomised 17 volunteers to GFR measurement by plasma clearance (PC) and renal clearance (RC) of either a single bolus of Iohexol (SBI; routine method), or of a continuous infusion of low dose Iohexol (CILDI; experimental method) at 0.5 mL/h for 12 h. GFR was measured by the alternative method after a washout period (4–28 days). Iohexol concentration was measured by high performance liquid chromatography/electrospray tandem mass spectrometry and time to steady state concentration (Css) determined. RESULTS: Mean PC was 76.7 ± 28.5 mL/min/1.73 m(2) (SBI), and 78.9 ± 28.6 mL/min/1.73 m(2) (CILDI), p = 0.82. No crossover effects occurred (p = 0.85). Correlation (r) between the methods was 0.98 (p < 0.0001). Bias was 2.2 mL/min/1.73 m(2) (limits of agreement −8.2 to 12.6 mL/min/1.73 m(2)) for CILDI. PC overestimated RC by 7.1 ± 7.3 mL/min/1.73 m(2). Mean intra-individual variation in GFR (CILDI) was 10.3% (p < 0.003). Mean ± SD Css was 172 ± 185 min. CONCLUSION: We hypothesise that changes in GFR >10.3% depict evolving AKI. If this were applicable to AKI, this is less than the 50% change in serum creatinine currently required to define AKI. CILDI is now ready for testing in patients with AKI. TRIAL REGISTRATION: This trial was registered with the European Union Clinical Trials Register (https://www.clinicaltrialsregister.eu/), registration number: 2010-019933-89. BioMed Central 2015-02-12 /pmc/articles/PMC4336474/ /pubmed/25885409 http://dx.doi.org/10.1186/s12967-015-0414-3 Text en © Dixon et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Dixon, John J
Lane, Katie
Dalton, R Neil
Turner, Charles
Grounds, R Michael
MacPhee, Iain AM
Philips, Barbara J
Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial
title Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial
title_full Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial
title_fullStr Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial
title_full_unstemmed Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial
title_short Validation of a continuous infusion of low dose Iohexol to measure glomerular filtration rate: randomised clinical trial
title_sort validation of a continuous infusion of low dose iohexol to measure glomerular filtration rate: randomised clinical trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336474/
https://www.ncbi.nlm.nih.gov/pubmed/25885409
http://dx.doi.org/10.1186/s12967-015-0414-3
work_keys_str_mv AT dixonjohnj validationofacontinuousinfusionoflowdoseiohexoltomeasureglomerularfiltrationraterandomisedclinicaltrial
AT lanekatie validationofacontinuousinfusionoflowdoseiohexoltomeasureglomerularfiltrationraterandomisedclinicaltrial
AT daltonrneil validationofacontinuousinfusionoflowdoseiohexoltomeasureglomerularfiltrationraterandomisedclinicaltrial
AT turnercharles validationofacontinuousinfusionoflowdoseiohexoltomeasureglomerularfiltrationraterandomisedclinicaltrial
AT groundsrmichael validationofacontinuousinfusionoflowdoseiohexoltomeasureglomerularfiltrationraterandomisedclinicaltrial
AT macpheeiainam validationofacontinuousinfusionoflowdoseiohexoltomeasureglomerularfiltrationraterandomisedclinicaltrial
AT philipsbarbaraj validationofacontinuousinfusionoflowdoseiohexoltomeasureglomerularfiltrationraterandomisedclinicaltrial